
Processa Pharmaceuticals (PCSA) Stock Forecast & Price Target
Processa Pharmaceuticals (PCSA) Analyst Ratings
Bulls say
Processa Pharmaceuticals Inc. has narrowed its full-year 2026 net loss per share estimate to $0.15 from $0.20, indicating improved financial projections due to an increase in the outstanding share count. The company anticipates that positive interim data from the NGC-Cap mid-stage trial could serve as a significant value inflection point, potentially enhancing investor confidence. Furthermore, Processa's recent strategic investment and exploration of corporate cryptocurrency treasury strategies highlight its commitment to innovative financial management and growth objectives, reinforcing a positive outlook on its stock.
Bears say
Processa Pharmaceuticals is projected to incur a significant net loss of $0.43 per share for the full year 2025, reflecting ongoing financial challenges. In addition, the company faces various operational risks, including potential delays in regulatory approvals, intense competitive pressures that could hinder market penetration and pricing, and the possibility of dilution in the near to medium term. Furthermore, the company's recent net loss of $0.25 per share aligns closely with forecasts, indicating that the financial outlook remains under strain amid these uncertainties.
This aggregate rating is based on analysts' research of Processa Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Processa Pharmaceuticals (PCSA) Analyst Forecast & Price Prediction
Start investing in Processa Pharmaceuticals (PCSA)
Order type
Buy in
Order amount
Est. shares
0 shares